Gene transfer for ischemic cardiovascular disease: Is this the end of the beginning or the beginning of the end?

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 3, 2005, Pages 138-144

  Pislaru, Sorin V ^a   Simari, Robert D ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Angiogenesis; Clinical trials; Gene therapy; Vectors

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; DIURETIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1; LIPOSOME; PLACEBO; PLASMID VECTOR; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANGIOGENESIS; ANGIOPLASTY; BINDING AFFINITY; BUERGER DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DNA MODIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT FAILURE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ARTERIAL OCCLUSIVE DISEASES; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 20444452567     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0136     Document Type: Review

References (50)

1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
2. Serruys PW et al. (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331: 489-495
3. Fischman DL et al. (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331: 496-501
4. Isner JM et al. (2001) Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 89: 389-400
5. Nabel EG et al. (1989) Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 244: 1342-1344
6. Wilson JM et al. (1989) Implantation of vascular grafts lined with genetically modified endothelial cells. Science 244: 1344-1346
7. Simari R et al. (1996) Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 98: 225-235
8. Yanagisawa-Miwa A et al. (1992) Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257: 1401-1403
9. Cross MJ and Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22: 201-207
10. Tsurumi Y et al. (1996) Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94: 3281-3290
11. 165 in patient with ischaemic limb. Lancet 348: 370-374
12. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123
13. Baumgartner I et al. (2000) Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132: 880-884
14. Isner JM et al. (1998) Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 28: 964-973
15. Shyu KG et al. (2003) Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 114: 85-92
16. Makinen K et al. (2002) Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 6: 127-133
17. Rajagopalan S et al. (2002) Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 90: 512-516
18. Rajagopalan S et al. (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938
19. Comerota AJ et al. (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35: 930-936
20. Morishita R et al. (2004) Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44: 203-209
21. Rajagopalan S et al. (2004) Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther 15: 619-24
22. Laitinen M et al. (1998) Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 9: 1481-1486
23. Freedman SB et al. (2002) Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther 13: 1595-1603
24. 165 as sole therapy for myocardial ischemia. Circulation 98: 2800-2804
25. Symes JF et al. (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68: 830-836
26. 165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102: 965-974
27. 165 as sole therapy in patients with refractory coronary artery disease - 12-month follow-up: angiogenic gene therapy. J Intern Med 250: 373-381
28. Kolsut P et al. (2003) Gene therapy of coronary artery disease with phvegf165 - early outcome. Kardiol Pol 59: 373-384
29. Huwer H et al. (2001) Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease. Eur J Cardiothorac Surg 20: 1128-134
30. Lathi KG et al. (2001) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 92: 19-25
31. Vale PR et al. (1999) Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. J Am Coll Cardiol 34: 246-254
32. Vale PR et al. (2001) Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103: 2138-2143
33. Losordo DW et al. (2002) Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012-2018
34. Losordo DW and Dimmeler S (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 109: 2487-2491
35. Rosengart TK et al. (1999) Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468-474
36. Giordano FJ et al. (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2: 534-539
37. Grines C et al. (2002) Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105: 1291-1297
38. Grines CL et al. for the Angiogenic GENe Therapy (AGENT-2) Study Group (2003) A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42: 1339-1347
39. Ueda H et al. (1999) Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thorac Surg 67: 1726-1731
40. Zhong J et al. (2003) Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest 112: 30-41
41. Shyu KG et al. (2002) Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 54: 576-583
42. Green LA et al. (2002) Indirect monitoring of endogenous gene expression by positron emission tomography (PET) imaging of reporter gene expression in transgenic mice. Mol Imaging Biol 4: 71-81
43. Wu JC et al. (2002) Optical imaging of cardiac reporter gene expression in living rats. Circulation 105: 1631-1634
44. Wu JC et al. (2004) Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 110: 685-691
45. Peng KW et al. (2002) Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 8: 527-531
46. Baker AH (2004) Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 84: 279-299
47. Losordo DW and Dimmeler S (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 109: 2692-2697
48. Ikeda Y et al. (2004) Development of angiogenic cell and gene therapy by transplantation of umbilical cord blood with vascular endothelial growth factor gene. Hypertens Res 27: 119-128
49. Askari A et al. (2004) Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. J Am Coll Cardiol 43: 1908-1914
50. Iwaguro H et al. (2002) Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105: 732-738